BeOne Medicines (ONC) Current Deferred Revenue (2015 - 2023)

BeOne Medicines (ONC) has 8 years of Current Deferred Revenue data on file, last reported at $159.0 million in Q2 2023.

• On a quarterly basis, Current Deferred Revenue fell 2.67% year-over-year to $159.0 million in Q2 2023; TTM through Jun 2023 was $159.0 million, a 2.67% decrease from a year earlier, with the FY2022 full-year figure at $213.9 million, down 28.71% from the prior year.
• Current Deferred Revenue for Q2 2023 stood at $159.0 million, down from $185.5 million in the prior quarter.
• Over the last five years, Current Deferred Revenue for ONC reached as high as $300.0 million in Q4 2021 and fell as low as $17.5 million in Q1 2019.
• Historically, Current Deferred Revenue has averaged $141.4 million across 4 years, with a median of $159.0 million in 2023.
• On a YoY basis, Current Deferred Revenue climbed as much as 156.89% in 2022 and fell as far as 28.71% in 2022.
• Year by year, Current Deferred Revenue stood at $17.5 million in 2019, then surged by 1613.89% to $300.0 million in 2021, then fell by 28.71% to $213.9 million in 2022, then dropped by 25.64% to $159.0 million in 2023.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were $159.0 million in Q2 2023, $185.5 million in Q1 2023, and $213.9 million in Q4 2022.